PK/PD model prediction of platelet reduction to guide phase III dose selection for navitoclax added on to ruxolitinib in myelofibrosis
Nuthalapati, S. Holes, L. Prchal, J. Harrison, C. Somervaille, Tim C P Hayslip, J. Potluri, J. Menon, R. Mensing, S.
Nuthalapati, S.
Holes, L.
Prchal, J.
Harrison, C.
Somervaille, Tim C P
Hayslip, J.
Potluri, J.
Menon, R.
Mensing, S.
Citations
Altmetric:
Abstract
None
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Nuthalapati S, Holes L, Prchal J, Harrison C, Somervaille TCP, Hayslip J, et al. PK/PD model prediction of platelet reduction to guide phase III dose selection for navitoclax added on to ruxolitinib in myelofibrosis. Clinical Pharmacology & Therapeutics. 2021;109.